Last reviewed · How we verify

Standard of Care Treatment

Janssen Research & Development, LLC · Phase 3 active Small molecule

Standard of Care Treatment is a PD-1 inhibitor Small molecule drug developed by Janssen Research & Development, LLC. It is currently in Phase 3 development for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Urothelial carcinoma. Also known as: cytoxan.

This drug works by inhibiting the PD-1 receptor, which helps the immune system recognize and attack cancer cells.

This drug works by inhibiting the PD-1 receptor, which helps the immune system recognize and attack cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Urothelial carcinoma.

At a glance

Generic nameStandard of Care Treatment
Also known ascytoxan
SponsorJanssen Research & Development, LLC
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

By blocking the PD-1 receptor, the drug allows the immune system to function more effectively, leading to the destruction of cancer cells. This mechanism is often referred to as immunotherapy. The drug's ability to inhibit the PD-1 receptor is key to its therapeutic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard of Care Treatment

What is Standard of Care Treatment?

Standard of Care Treatment is a PD-1 inhibitor drug developed by Janssen Research & Development, LLC, indicated for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Urothelial carcinoma.

How does Standard of Care Treatment work?

This drug works by inhibiting the PD-1 receptor, which helps the immune system recognize and attack cancer cells.

What is Standard of Care Treatment used for?

Standard of Care Treatment is indicated for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Urothelial carcinoma, Melanoma, Renal cell carcinoma.

Who makes Standard of Care Treatment?

Standard of Care Treatment is developed by Janssen Research & Development, LLC (see full Janssen Research & Development, LLC pipeline at /company/johnson-johnson).

Is Standard of Care Treatment also known as anything else?

Standard of Care Treatment is also known as cytoxan.

What drug class is Standard of Care Treatment in?

Standard of Care Treatment belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is Standard of Care Treatment in?

Standard of Care Treatment is in Phase 3.

What are the side effects of Standard of Care Treatment?

Common side effects of Standard of Care Treatment include Pneumonitis, Hypothyroidism, Hyperthyroidism, Diarrhea, Fatigue, Nausea.

What does Standard of Care Treatment target?

Standard of Care Treatment targets PD-1 and is a PD-1 inhibitor.

Related